Balaxi Pharmaceuticals Limited
NSE: BALAXI · Pharmaceuticals
Limited coverage
We are not actively covering this company or have limited coverage today. Click to request coverage.
Snapshot
Unlock Balaxi Pharmaceuticals Limited's vital signs
Growth · Profitability · Valuation · Strength · Conviction
Company Overview
Business
Balaxi Pharmaceuticals is an IPR-based pharmaceutical company that focuses on the development, supply, and distribution of branded and generic medicines. The company primarily operates in frontier markets across Africa and Latin America.
Business Model
The company generates revenue by leveraging its IPR-based portfolio to supply prescription and OTC drugs through a network of warehouses in international frontier markets.
- Registered Products:897
- Warehouses:38
Growth Outlook
Growth is driven by the expansion of its product portfolio and the strengthening of its distribution infrastructure across its seven operational countries.
- Operational Countries:7
Key Risks
- Currency Volatility. Operating in frontier markets exposes the company to significant foreign exchange fluctuations that can impact profitability.
- Regulatory Risk. Changes in pharmaceutical registration requirements and healthcare policies in African and Latin American markets may disrupt supply chains.
- Geopolitical Instability. Political unrest or economic instability in target frontier regions could adversely affect business operations and product distribution.
Start your research today
Unlock AI insights, financials, peers and live data on Balaxi Pharmaceuticals Limited and 5,000+ companies — free.
Key Metrics
P/E
85.9x
Q4 FY26 · consolidated
EV/EBITDA
14.8x
Q4 FY26 · consolidated
NET PROFIT MARGIN
0.9%
Q4 FY26 · consolidated
DEBT TO EQUITY
0.2x
Q4 FY26 · consolidated
Peers · Pharmaceuticals
| Company | Mkt Cap | P/E | EV/EBITDA | Rev Gr YoY | EBITDA Mgn | ROE | ROCE | 1Y Return |
|---|---|---|---|---|---|---|---|---|
Balaxi Pharmaceuticals LimitedBALAXI | ₹127 Cr | 85.92 | 14.79 | — | 4.2% | 0.6% | 3.5% | -49.8% |
TranschemTRANSCHEM | ₹502 Cr | 75.62 | 52.99 | -100.0% | 177.7% | 8.3% | 10.6% | +600.8% |
Albert DavidALBERTDAVD | ₹501 Cr | 21.67 | 13.19 | 11.4% | 11.0% | 5.8% | 7.5% | +10.3% |
Haleos Labs LimitedHALEOSLABS | ₹457 Cr | 28.51 | 12.83 | -3.1% | 13.6% | 7.4% | 10.3% | — |
Medicamen BiotecMEDICAMEQ | ₹434 Cr | 43.00 | 19.76 | 24.7% | 11.3% | 4.1% | 6.2% | +5.9% |
Jenburkt Pharmaceuticals LimitedJENBURPH | ₹420 Cr | 12.30 | 8.20 | — | 30.0% | 16.7% | 21.5% | -15.2% |
As of Q4 FY26
Financials
Balaxi Pharmaceuticals Limited
NSE: BALAXI · Pharmaceuticals
Limited coverage
We are not actively covering this company or have limited coverage today. Click to request coverage.
Snapshot
Unlock Balaxi Pharmaceuticals Limited's vital signs
Growth · Profitability · Valuation · Strength · Conviction
Company Overview
Business
Balaxi Pharmaceuticals is an IPR-based pharmaceutical company that focuses on the development, supply, and distribution of branded and generic medicines. The company primarily operates in frontier markets across Africa and Latin America.
Business Model
The company generates revenue by leveraging its IPR-based portfolio to supply prescription and OTC drugs through a network of warehouses in international frontier markets.
- Registered Products:897
- Warehouses:38
Growth Outlook
Growth is driven by the expansion of its product portfolio and the strengthening of its distribution infrastructure across its seven operational countries.
- Operational Countries:7
Key Risks
- Currency Volatility. Operating in frontier markets exposes the company to significant foreign exchange fluctuations that can impact profitability.
- Regulatory Risk. Changes in pharmaceutical registration requirements and healthcare policies in African and Latin American markets may disrupt supply chains.
- Geopolitical Instability. Political unrest or economic instability in target frontier regions could adversely affect business operations and product distribution.
Start your research today
Unlock AI insights, financials, peers and live data on Balaxi Pharmaceuticals Limited and 5,000+ companies — free.
Key Metrics
P/E
85.9x
Q4 FY26 · consolidated
EV/EBITDA
14.8x
Q4 FY26 · consolidated
NET PROFIT MARGIN
0.9%
Q4 FY26 · consolidated
DEBT TO EQUITY
0.2x
Q4 FY26 · consolidated
Peers · Pharmaceuticals
As of Q4 FY26